Cabotegravir and Rilpivirine

  • Recently, the UK’s National Institute for Health and Care Excellence (NICE) has recommended the country’s first long-acting injectable treatment for HIV-1 infection in adults.
  • Cabotegravir with Rilpivirine is recommended as an option for adults with HIV-1 infection.
  • Currently treatment for HIV involves lifelong antiretroviral tablets that need to be taken every day, which keep viral loads to levels at which the infection cannot be detected and transmitted between individuals.
  • Clinical trial results show that Cabotegravir with Rilpivirine is as effective as oral antiretrovirals at keeping the viral load ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content

Already a Member? Login here

Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material since 2018 of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Be an Annual Subscriber

News Snippets